A Look At Healthcare Stock – VHT

A Look At Healthcare Stock - VHT

Volpara Health Technologies Limited (ASX: VHT) is a health sector company of New Zealand and a leading provider of breast imaging analytics and analysis products that deliver personalised breast cancer screening software applications. The AI imaging technologies available with the Volpara helps in the early detection of breast cancer.

Volpara Health Technologies was established in 2009 by the world’s leading breast imaging experts.  The company aims at reducing the mortality and cost of breast cancer through Volpara software. The company got officially listed on ASX on 27th April 2016.

In early April, the company announced the Quarterly Cash Flow Report for the quarter ending 31 March 2019. The company reported an Annual Recurring Revenue (ARR) of NZ$6.63M in Q419 which is 86% higher than the figures of Q418. This signifies a robust growth in its revenue as compared to the prior corresponding period.

The cash receipts from the customers increased by 27% from Q4 FY18 to NZ$1.04M in Q4 FY19. The cash receipts of Volpara crossed the 1-million mark for the third straight quarter. The total contracts signed during the period were up by 42% to NZ$15.8M in FY19 in comparison to FY18. The number of women receiving the advantage of Volpara’s technology has increased in the US, and at present around 7.1% of the US women are screened per year using the company’s technology.

According to the CEO of Volpara Health Technologies, the FY 2019 ended on a positive note for the company. The company partnered with several clinics during the quarter including Australia’s I-MED Radiology Network.

In the first week of April, Volpara provided information on the new issue of options. The company will issue 40,000 Options at an exercise price of A$1.19, expiring on 28 March 2026. The options will be issued to the new employees to encourage long-term alignment of new employees to the business. The maturity date of the options would be segregated as – 40 per cent on two years from the grant date, 20 per cent on three years from the grant date, 20 per cent on four years from the grant date and the remaining 20 per cent on five years from the grant date.

Sponsored ad by Kalkine

Late in March, the company made an announcement leading to its expansion of association with GE Healthcare. This development was done to expand the company’s coverage outside the US and to deliver an excellent breast health care to the female consumers.

The company’s stock ended up at AUD 1.715, down by 0.867% (as on 3 May 2019) as compared to the previous day’s stock market price. Around 179.8 million shares were outstanding with 263,127 number of shares in trade today. The market capitalisation of the company was recorded as AUD 311.05 million. The 52-week high and low stock market value was AUD 1.945 and AUD 0.610 respectively. The YTD of the company’s stock stood at 57.27% with its six-month growth being 29.10%.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report

LEAVE A REPLY

Please enter your comment!
Please enter your name here